JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

230.39 -3.7

Overview

Share price change

24h

Current

Min

226.28

Max

239.25

Key metrics

By Trading Economics

Income

28M

-33M

Sales

32M

245M

Profit margin

-13.56

Employees

1,189

EBITDA

68M

15M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+23.44% upside

Dividends

By Dow Jones

Next Earnings

30 kwi 2026

Market Stats

By TradingEconomics

Market Cap

1.5B

15B

Previous open

234.09

Previous close

230.39

News Sentiment

By Acuity

50%

50%

179 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 kwi 2026, 00:00 UTC

Major News Events

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 kwi 2026, 23:33 UTC

Earnings

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 kwi 2026, 22:40 UTC

Earnings

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:11 UTC

Earnings

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 kwi 2026, 21:01 UTC

Earnings

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 kwi 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 kwi 2026, 23:34 UTC

Market Talk
Major News Events

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 kwi 2026, 23:16 UTC

Earnings

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 kwi 2026, 23:15 UTC

Earnings

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 kwi 2026, 22:52 UTC

Earnings

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 kwi 2026, 22:51 UTC

Earnings

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 kwi 2026, 22:30 UTC

Earnings

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 kwi 2026, 22:30 UTC

Earnings

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 kwi 2026, 22:29 UTC

Earnings

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 kwi 2026, 22:27 UTC

Earnings

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 kwi 2026, 22:06 UTC

Market Talk
Earnings

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:47 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:37 UTC

Earnings

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 kwi 2026, 21:34 UTC

Earnings

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 kwi 2026, 21:29 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:20 UTC

Market Talk
Earnings

Tesla Expands Manufacturing to Chips -- Market Talk

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

23.44% upside

12 Months Forecast

Average 296.62 USD  23.44%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

13

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

179 / 348 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

$

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
help-icon Live chat